Cephalalgia最新文献

{"title":"Glucocorticoid signaling mediates stress-induced migraine-like behaviors in a preclinical mouse model.","authors":"Ya-Yu Hu, Rimenez Souza, Athithyaa Muthuraman, Leela Knapp, Christa McIntyre, Gregory Dussor","doi":"10.1177/03331024241277941","DOIUrl":"10.1177/03331024241277941","url":null,"abstract":"<p><strong>Background: </strong>Stress is one of the most common precipitating factors in migraine and is identified as a trigger in nearly 70% of patients. Responses to stress include release of glucocorticoids as an adaptive mechanism, but this may also contribute to migraine attacks. Here, we investigated the role of glucocorticoids on stress-induced migraine-like behaviors.</p><p><strong>Methods: </strong>We have shown previously that repeated stress in mice evokes migraine-like behavioral responses and priming to a nitric oxide donor. Metyrapone, mifepristone, and corticosterone (CORT) were used to investigate whether CORT contributes to the stress-induced effects. Facial mechanical hypersensitivity was evaluated by von Frey testing and grimace scoring assessed the presence of non-evoked pain. We also measured serum CORT levels in control, stress, and daily CORT injected groups of both male and female mice.</p><p><strong>Results: </strong>Metyrapone blocked stress-induced responses and priming in male and female mice. However, repeated CORT injections in the absence of stress only led to migraine-like behaviors in females. Both female and male mice showed similar patterns of serum CORT in response to stress or exogenous administration. Finally, administration of mifepristone, the glucocorticoid receptor antagonist, prior to each stress session blocked stress-induced behavioral responses in male and female mice.</p><p><strong>Conclusions: </strong>These findings demonstrate that while CORT synthesis and receptor activation is necessary for the behavioral responses triggered by repeated stress, it is only sufficient in females. Better understanding of how glucocorticoids contribute to migraine may lead to new therapeutic opportunities.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241277941"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11578425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"What predicts citation counts and translational impact in headache research? A machine learning analysis\".","authors":"Igor Petrušić, Paolo Martelletti","doi":"10.1177/03331024241266980","DOIUrl":"https://doi.org/10.1177/03331024241266980","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241266980"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and clinical features of short-lasting unilateral neuralgiform headache attacks: A systematic review and meta-analysis.","authors":"Johanne Gry Larsen, Mikkel Johannes Henningsen, William Kristian Karlsson, Rune Häckert Christensen, Haidar Muhsen Al-Khazali, Faisal Mohammad Amin, Håkan Ashina","doi":"10.1177/03331024241271976","DOIUrl":"10.1177/03331024241271976","url":null,"abstract":"<p><strong>Background: </strong>To synthesize the available epidemiologic data on short-lasting unilateral neuralgiform headache attacks (SUNHA). This, in turn, might inform diagnostic work-up and clinical decision-making.</p><p><strong>Methods: </strong>EMBASE and PubMed were searched for observational studies reporting on the prevalence or relative frequency of SUNHA or its individual clinical features. Two investigators independently conducted title and abstract screening, full-text review, data extraction, and risk of bias assessment, and random-effects meta-analyses were performed to estimate the prevalence or relative frequency of SUNHA and its individual clinical features.</p><p><strong>Results: </strong>Fifteen clinic-based studies met our eligibility criteria. Of these, five studies reported estimates on the relative frequency of SUNHA among adults evaluated for headache or facial pain, yielding a pooled relative frequency as 0.32% (95% confidence interval = 0.17-0.62; <i>I</i>²<i></i>= 89.9%). Most often, SUNHA presented as episodic, side-locked stabbing headache of severe pain intensity, predominantly affecting the ophthalmic and/or maxillary branch of the trigeminal nerve. The most common cranial autonomic features were lacrimation, conjunctival injection, rhinorrhea and nasal congestion.</p><p><strong>Conclusions: </strong>SUNHA is a rare headache disorder with distinct clinical features. However, our findings must be interpreted with caution as a result of between-study heterogeneity and lack of population-based studies, underscoring the need for further epidemiologic research.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241271976"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action.","authors":"Mario Fernando Prieto Peres, Simona Sacco, Patricia Pozo-Rosich, Cristina Tassorelli, Fayyaz Ahmed, Rami Burstein, Sait Ashina, Derya Uluduz, Andreas Kattem Husøy, Timothy J Steiner","doi":"10.1177/03331024241267309","DOIUrl":"https://doi.org/10.1177/03331024241267309","url":null,"abstract":"<p><p>The Global Burden of Disease (GBD) study is pivotal in shaping health policies by providing comprehensive data on mortality and disability. An updated GBD2021 analysis, published in <i>Lancet Neurology</i> on 14 March 2024, expands the scope of neurological disorders to include 37 conditions, revealing their significant impact on global health. Neurological disorders affect 3.4 billion people, or 43.1% of the global population, making them the leading cause of disability-adjusted life years (DALYs) in 2021, with an 18.2% increase since 1990. The top three causes of DALYs in this category are stroke, neonatal encephalopathy and migraine. Migraine, affecting 1.16 billion people, ranks first among children and adolescents and second among adults aged under 60 years. Despite its substantial impact, migraine often lacks proper attention because of its non-fatal nature, invisibility and historical neglect of neurological disorders. The International Headache Society calls for recognizing migraine as a serious medical condition, promoting research and integrating migraine management into public health strategies. Effective interventions include raising awareness, improving access to treatment, adding migraine to the epidemiological surveillance agenda and exploring new treatment strategies. A coordinated effort among stakeholders is essential to alleviate the burden of migraine on individuals and society.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241267309"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142092463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced learning in migraine: False positive finding or discovery of a new migraine trait?","authors":"Petter Moe Omland","doi":"10.1177/03331024241268297","DOIUrl":"https://doi.org/10.1177/03331024241268297","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241268297"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141896941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase^®.","authors":"Sylvie Favrelière, Julien Mahé, Gwenaelle Veyrac, Jean Philippe Neau, Claire Lafay-Chebassier, Marie Christine Pérault-Pochat","doi":"10.1177/03331024241267316","DOIUrl":"https://doi.org/10.1177/03331024241267316","url":null,"abstract":"<p><strong>Background: </strong>Data on drug-induced reversible cerebral vasoconstriction syndrome (RCVS) are scarce. We aimed to describe RCVS characteristics with drugs previously identified as associated with RCVS and investigate potential signals related to other drugs.</p><p><strong>Methods: </strong>VigiBase^® was queried for all reports of RCVS until 31 May 2023. A descriptive study was performed on reports concerning drug classes known to precipitate RCVS. To identify new drugs, a disproportionality analysis was conducted.</p><p><strong>Results: </strong>In total, 560 reports were included. RCVS occurred in patients aged between 45-64 years (40%) and 18-44 years (35%), mainly in females (72.5%). Drugs were antidepressants (38.4%), triptans (6.4%), nasal decongestants (3.7%) and immunosupressants (8.7%). In 50 cases, antidepressants were in association with drugs known to precipitate RCVS. The median time to onset was 195 days for antidepressants and much shorter (1-10 days) for triptans, nasal decongestants and immunosuppressants. The outcome was favorable in 87% of cases, and fatal in 4.4%. We found a disproportionality signal with 14 drugs: glucocorticoids, bupropion, varenicline, mycophenolic acid, aripiprazole, trazodone, monoclonal antibodies (erenumab, ustekinumab and tocilizumab), leuprorelin and anastrozole.</p><p><strong>Conclusions: </strong>The present study confirms the role of vasoconstrictors in the onset of RCVS, particularly when used in combination and found potential signals, which may help clinicians envisage an iatrogenic etiology of RCVS.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241267316"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Headache Society global practice recommendations for the acute pharmacological treatment of migraine.","authors":"Francesca Puledda, Simona Sacco, Hans-Christoph Diener, Messoud Ashina, Haidar M Al-Khazali, Sait Ashina, Rami Burstein, Eric Liebler, Andrea Cipriani, Min Kyung Chu, Alexandra Cocores, Freda Dodd-Glover, Esme Ekizoğlu, David Garcia-Azorin, Carl Göbel, Maria Teresa Goicochea, Amr Hassan, Koichi Hirata, Jan Hoffmann, Bronwyn Jenkins, Katharina Kamm, Mi Ji Lee, Yu-Hsiang Ling, Marco Lisicki, Daniele Martinelli, Teshamae S Monteith, Raffaele Ornello, Aynur Ozge, Mario Peres, Patricia Pozo-Rosich, Volodymyr Romanenko, Todd J Schwedt, Marcio Nattan P Souza, Tsubasa Takizawa, Gisela M Terwindt, Janu Thuraiaiyah, Mansoureh Togha, Nicolas Vandenbussche, Shuu-Jiun Wang, Shengyuan Yu, Cristina Tassorelli","doi":"10.1177/03331024241252666","DOIUrl":"https://doi.org/10.1177/03331024241252666","url":null,"abstract":"<p><strong>Background: </strong>In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications.</p><p><strong>Methods: </strong>An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group.</p><p><strong>Results: </strong>A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained.</p><p><strong>Conclusion: </strong>Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241252666"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Open label experience of repeated OnabotulinumtoxinA injections towards the sphenopalatine ganglion in patients with chronic cluster headache and chronic migraine.","authors":"Lucy Simmonds, Kent Are Jamtøy, Irina Aschehoug, Sozaburo Hara, Tore W Meisingset, Manjit S Matharu, Erling Tronvik, Daniel Fossum Bratbak","doi":"10.1177/03331024241273967","DOIUrl":"https://doi.org/10.1177/03331024241273967","url":null,"abstract":"<p><strong>Background: </strong>A novel technique for injection of OnabotulinumtoxinA (BTA) towards the sphenopalatine ganglion (SPG) has shown promise in refractory chronic migraine (CM) and chronic cluster headache (CCH). Open label safety and efficacy data are presented here.</p><p><strong>Methods: </strong>Patients with refractory CM or CCH who had received at least one injection and completed headache diaries were included. Efficacy was defined as ≥50% reduction in moderate-to-severe headache days for CM, or ≥50% reduction in attack frequency for CCH, at weeks five to eight.</p><p><strong>Results: </strong>Over 261 injections, there were 123 adverse events (AE), of which one was serious. Most (93%) AEs were mild and all were transient. The 50% response to one injection was 81% for CM and 69% for CCH. The response gradually reduced over subsequent months for CM but stayed between 55% and 67% for CCH. Repeated injections were beneficial.</p><p><strong>Conclusions: </strong>Injections resulted in improvement for both groups and was maintained with repeated injections. Repeat injection after three months may be beneficial in CM. Adverse events were not uncommon, but universally transient, presumably as a result of the mechanism of action of BTA. Repeated BTA injection towards the SPG could be an effective treatment for refractory CM and CCH. Larger, randomised, placebo-controlled trials are required.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 8","pages":"3331024241273967"},"PeriodicalIF":5.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine.","authors":"Tessa de Vries, Deirdre M Boucherie, Kayi Y Chan, Eloísa Rubio-Beltrán, Alejandro Labastida-Ramírez, Sieneke Labruijere, Saurabh Gupta, Antoon van den Bogaerdt, Arnaud Vincent, Ruben Dammers, A H Jan Danser, Antoinette MaassenVanDenBrink","doi":"10.1177/03331024241254088","DOIUrl":"10.1177/03331024241254088","url":null,"abstract":"<p><strong>Background: </strong>Migraine prevalence and levels of calcitonin gene-related peptide (CGRP), a peptide involved in migraine pathophysiology, differ between men and women, and appear to be affected by changes in sex hormones. The present study investigated the sex-specific responses to CGRP in human isolated arteries.</p><p><strong>Methods: </strong>CGRP-induced relaxation of 62 (28 men and 34 women) human isolated middle meningeal arteries (HMMA) and 139 (69 men and 70 women) human isolated coronary arteries (HCA) was compared between men and women in groups <50 years and ≥50 years of age as a proxy for pre- and postmenopausal status in women, as well as matched-age groups for men.</p><p><strong>Results: </strong>In HCA, no differences were observed between male and female tissue, or between the different age groups. However, in HMMA, the maximum response was significantly smaller and CGRP was less potent in females <50 compared with males <50 years of age. No differences were observed between the older age groups.</p><p><strong>Conclusions: </strong>Sex differences were observed for CGRP-induced relaxation of HMMA, but not HCA. These differences could arise from differential receptor expression in the vascular beds combined with the effect of sex hormones on CGRP and subsequent receptor desensitization.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"44 7","pages":"3331024241254088"},"PeriodicalIF":5.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141751233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Minimal important difference of the Migraine Disability Assessment (MIDAS): Longitudinal data from the DMKG Headache Registry.","authors":"Ruth Ruscheweyh, Stefanie Förderreuther, Tobias Freilinger, Charly Gaul, Gudrun Goßrau, Tim Patrick Jürgens, Torsten Kraya, Lars Neeb, Victoria Ruschil, Jörg Scheidt, Thomas Dresler","doi":"10.1177/03331024241261077","DOIUrl":"10.1177/03331024241261077","url":null,"abstract":"<p><strong>Background: </strong>The Migraine Disability Assessment (MIDAS) is widely used. However, there are limited data on how much a reduction in the MIDAS score indicates a change that matters to the patient.</p><p><strong>Methods: </strong>Data from the DMKG (i.e. German Migraine and Headache Society) Headache Registry were used to determine the minimal important difference (MID) of the MIDAS, using the Patient Global Impression of Change (PGIC) as anchor and applying average change and receiver operating characteristic curve methods.</p><p><strong>Results: </strong>In total, 1218 adult migraine patients (85.6% female, 40.2 ± 12.8 years, baseline MIDAS 44.2 ± 47.4, follow-up MIDAS 36.5 ± 45.3) were included. For patients with baseline MIDAS >20 (MIDAS grade IV, n = 757), different methods using PGIC \"somewhat improved\" as anchor yielded percent change MIDs of the MIDAS between -29.4% and -33.2%. For baseline MIDAS between 6 and 20 (grades II and III, n = 334), using PGIC \"much improved\" as anchor, difference change MIDs were between -3.5 and -4.5 points.</p><p><strong>Conclusions: </strong>Based on the above results, we estimated the MID of the MIDAS at -30% for patients with a baseline MIDAS >20, and at -4 points for those with a baseline MIDAS of 6-20, for a tertiary headache care population.</p><p><strong>Trial registration: </strong>The DMKG Headache Registry is registered with the German Clinical Trials Register (DRKS 00021081).</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":" ","pages":"3331024241261077"},"PeriodicalIF":5.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}